Gazyva: Phase IIIb data

Data from a cohort of 158 previously untreated CLL patients in the open-label, international Phase IIIb GREEN trial showed that IV Gazyva plus Treanda bendamustine led to an ORR of 78.5%, including 51 complete responses and 73 partial responses, plus 17 cases of stable disease. The combination led to MRD-negativity in blood and bone marrow in 58.9% and 27.8% of patients, respectively. The trial is enrolling about 950 patients with previously untreated or relapsed/refractory CLL to receive Gazyva alone or in combination with chemotherapy. Next month, data will be presented at the American Society of Hematology meeting in Orlando. ...